Research Papers

15 of 40 papers

CSV Excel
Quick filters: Open Data Open Code Pre-registered Funding Declared COI Declared Open Access Clear Filters
Descriptive study of the utility of individual tracking tool in program monitoring for prevention of mother-to-child tr…
Gupta RS; Hegde A; Mulik T; Yewale K; Babu PK; Pardeshi K; Balkrishnan S; Seguy N; Reddy DC.
Curr Opin HIV AIDS (Unknown)
Published: 2016
2/6 Transparent
Funding Declared
Operational feasibility of using whole blood in the rapid HIV testing algorithm of a resource-limited settings like Ban…
Munshi SU; Oyewale TO; Begum S; Uddin Z; Tabassum S.
Curr Opin HIV AIDS (Unknown)
Published: 2016
2/6 Transparent
Funding Declared
Use of technology in follow-up of HIV positive pregnant women and their babies till 18 months of age- an innovation by …
Gupta RS; Yewale K; Hegde AS; Mulik T; Bamrotiya M; Yadav S; Rane T; Pardeshi K; Balakrishnan S; Reddy DC.
Curr Opin HIV AIDS (Unknown)
Published: 2016
2/6 Transparent
Funding Declared
Getting to 90-90-90 targets for children and adolescents HIV in low and concentrated epidemics: bottlenecks, opportunit…
Kisesa A; Chamla D.
Curr Opin HIV AIDS (Unknown)
Published: 2016
2/6 Transparent
Funding Declared
Bottlenecks and opportunities for delivering integrated pediatric HIV services in Nepal.
Diese M; Shrestha L; Pradhan B; Singh D; Raaijmakers H; Kisesa A; Chamla D; Ntambue MA.
Curr Opin HIV AIDS (Unknown)
Published: 2016
2/6 Transparent
Funding Declared
Statistical issues in trials of preexposure prophylaxis.
Dunn DT; Glidden DV.
Curr Opin HIV AIDS (Unknown)
Published: 2016
2/6 Transparent
Funding Declared
Quasi-experiments to establish causal effects of HIV care and treatment and to improve the cascade of care.
Bor J; Geldsetzer P; Venkataramani A; Bärnighausen T.
Curr Opin HIV AIDS (Unknown)
Published: 2015
2/6 Transparent
Funding Declared
HIV treatment cascade in tuberculosis patients.
Lessells RJ; Swaminathan S; Godfrey-Faussett P.
Curr Opin HIV AIDS (Unknown)
Published: 2015
2/6 Transparent
Funding Declared
Long-acting antiviral agents for HIV treatment.
Margolis DA; Boffito M.
Curr Opin HIV AIDS (Unknown)
Published: 2015
2/6 Transparent
Funding Declared
Formulation and pharmacology of long-acting cabotegravir.
Trezza C; Ford SL; Spreen W; Pan R; Piscitelli S.
Curr Opin HIV AIDS (Unknown)
Published: 2015
2/6 Transparent
Funding Declared
Antibody engineering for increased potency, breadth and half-life.
Sievers SA; Scharf L; West AP; Bjorkman PJ.
Curr Opin HIV AIDS (Unknown)
Published: 2015
2/6 Transparent
Funding Declared
Modulation of HIV-1 immunity by adjuvants.
Moody MA.
Curr Opin HIV AIDS (Unknown)
Published: 2014
2/6 Transparent
Funding Declared
The emerging face of the HIV epidemic in the Middle East and North Africa.
Mumtaz GR; Riedner G; Abu-Raddad LJ.
Curr Opin HIV AIDS (Unknown)
Published: 2014
2/6 Transparent
Funding Declared
Immediate antiretroviral therapy in young HIV-infected children: benefits and risks.
Collins IJ; Judd A; Gibb DM.
Curr Opin HIV AIDS (Unknown)
Published: 2014
1/6 Transparent
The natural history of HIV infection.
Sabin CA; Lundgren JD.
Curr Opin HIV AIDS (Unknown)
Published: 2013
1/6 Transparent